CIK 0001048477
- Large accelerated filer
BIOMARIN PHARMACEUTICAL INC
Sign in to watch- Ticker
- BMRN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680397820
- Phone
- +1 415-506-6700
- Business address
- 105 DIGITAL DRIVE, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,466,459
- in 2 filings
Net −$1,466,459. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-01-27 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion | +8,333 | $26.49 | $221K | 303,885 |
| 2021-01-27 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale | −8,333 | $85.49 | $712K | 295,552 |
| 2021-01-27 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to buy Common Stock) | −8,333 | 131,180 | ||
| 2020-12-29 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale | −1,500 | $88.18 | $132K | 295,552 |
| 2020-12-28 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale | −1,500 | $88.77 | $133K | 297,052 |
| 2020-10-14 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Sale | −2,121 | $79.91 | $169K | 61,281 |
| 2020-10-07 | HERON ELAINE J Director | Exercise or conversion | +15,000 | $26.49 | $397K | 66,968 |
| 2020-10-07 | HERON ELAINE J Director | Exercise or conversion · Stock Option (Right to buy Common Stock) | −15,000 | 0 | ||
| 2020-08-31 | PYOTT DAVID E I Director | Purchase | +11,900 | $78.22 | $931K | 29,840 |
| 2020-08-31 | PYOTT DAVID E I Director | Purchase | +900 | $78.84 | $71K | 30,740 |
| 2020-08-03 | GREY MICHAEL G Director | Exercise or conversion | +2,500 | $26.49 | $66K | 45,340 |
| 2020-08-03 | GREY MICHAEL G Director | Sale | −2,500 | $120.35 | $301K | 42,840 |
| 2020-08-03 | GREY MICHAEL G Director | Exercise or conversion · Stock Option (Right to buy Common Stock) | −2,500 | 5,000 | ||
| 2020-07-20 | FUCHS HENRY J President, Worldwide R&D | Exercise or conversion | +1,250 | $67.81 | $85K | 104,245 |
| 2020-07-20 | FUCHS HENRY J President, Worldwide R&D | Exercise or conversion | +75,716 | $67.81 | $5.1M | 179,961 |
| 2020-07-20 | FUCHS HENRY J President, Worldwide R&D | Exercise or conversion | +49,423 | $63.10 | $3.1M | 229,384 |
| 2020-07-20 | FUCHS HENRY J President, Worldwide R&D | Sale | −126,389 | $130.00 | $16.4M | 102,995 |
| 2020-07-20 | FUCHS HENRY J President, Worldwide R&D | Exercise or conversion · Stock Option (Right to buy Common Stock) | −1,250 | 0 | ||
| 2020-07-20 | FUCHS HENRY J President, Worldwide R&D | Exercise or conversion · Stock Option (Right to buy Common Stock) | −75,716 | 0 | ||
| 2020-07-20 | FUCHS HENRY J President, Worldwide R&D | Exercise or conversion · Stock Option (Right to buy Common Stock) | −49,423 | 0 |
Page 34 of 36 · 707 trades